首页 正文

Review The Surgical clinics of North America. 2024 Jun;104(3):545-556. doi: 10.1016/j.suc.2023.11.005 Q12.82025

Clostridioides difficile Colitis

难辨梭菌结肠炎 翻译改进

Luke Pumiglia  1, Lexi Wilson  2, Laila Rashidi  3

作者单位 +展开

作者单位

  • 1 Department of General Surgery, Madigan Army Medical Center, 9040 Jackson Avenue, Joint Base Lewis-McChord, WA 98431, USA.
  • 2 Department of Colorectal Surgery, Swedish Medical Center, 747 Broadway, Seattle, WA 98122, USA.
  • 3 Department of Surgery, MultiCare Health Care System, Washington State University, 3124 19th Street Suite 220, Tacoma, WA 98405, USA. Electronic address: lrashidi@multicare.org.
  • DOI: 10.1016/j.suc.2023.11.005 PMID: 38677819

    摘要 Ai翻译

    Clostridioides difficile colitis is an important source of hospital-acquired diarrhea associated with antibiotic use. Symptoms are profuse watery diarrhea, typically following a course of antibiotics; however, some cases of fulminant disease may manifest with shock, ileus, or megacolon. Nonfulminant colitis is treated with oral fidaxomicin. C difficile colitis has a high potential for recurrence, and recurrent episodes are also treated with fidaxomicin. Bezlotoxumab is another medication that may be used in populations at high risk for further recurrence. Fulminant disease is treated with maximal medical therapy and early surgical consultation. Antibiotic stewardship is critical to preventing C difficile colitis.

    Keywords: Clostridioides difficile colitis; Fidaxomicin; Fulminant colitis; Hospital-acquired diarrhea; Toxins.

    Keywords:clostridioides difficile; colitis

    Copyright © The Surgical clinics of North America. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Surgical clinics of north america

    缩写:SURG CLIN N AM

    ISSN:0039-6109

    e-ISSN:1558-3171

    IF/分区:2.8/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Clostridioides difficile Colitis